The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...

Comparatively, GSK underperformed the UK market's 3% decline and the UK Pharmaceuticals industry's 4.8% dip over the last year, highlighting industry-wide pressures.

GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline ...

In the latest market close, GSK (GSK) reached $41.90, with a -1.04% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 0.52% for the day. Elsewhere, ...

GlaxoSmithKline PLC (GB:GSK) will announce second-quarter earnings for 2023 next week on July 26. According to TipRanks, the consensus EPS forecast is £0.35 per share, which is similar to the EPS ...

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...

GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and the EMA's acceptance of an application for Nucala's expanded use. Despite ...

GSK (GSK) closed at $37.56 in the latest trading session, marking a +0.59% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.43%.